FY2018 EPS Estimates for TherapeuticsMD Inc Increased by Oppenheimer (TXMD)

TherapeuticsMD Inc (NASDAQ:TXMD) – Stock analysts at Oppenheimer boosted their FY2018 earnings per share (EPS) estimates for shares of TherapeuticsMD in a note issued to investors on Monday, October 29th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings per share of ($0.64) for the year, up from their prior estimate of ($0.65). Oppenheimer has a “Buy” rating and a $14.00 price objective on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s Q4 2018 earnings at ($0.13) EPS, FY2019 earnings at ($0.21) EPS, FY2021 earnings at $0.52 EPS and FY2022 earnings at $0.78 EPS.

TXMD has been the subject of several other reports. Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research note on Friday, August 10th. Zacks Investment Research downgraded TherapeuticsMD from a “buy” rating to a “sell” rating in a research note on Wednesday, October 24th. ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, September 7th. Finally, JPMorgan Chase & Co. set a $11.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, August 15th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. TherapeuticsMD currently has a consensus rating of “Hold” and a consensus price target of $13.88.



Shares of TXMD opened at $4.89 on Thursday. The company has a current ratio of 7.88, a quick ratio of 7.79 and a debt-to-equity ratio of 0.94. TherapeuticsMD has a one year low of $4.30 and a one year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). The firm had revenue of $3.80 million during the quarter, compared to analyst estimates of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The business’s quarterly revenue was down 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) earnings per share.

In related news, CEO Robert G. Finizio sold 92,000 shares of the firm’s stock in a transaction dated Thursday, October 11th. The shares were sold at an average price of $5.65, for a total value of $519,800.00. Following the transaction, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at approximately $104,443,408.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $6.24, for a total transaction of $1,148,160.00. Following the completion of the transaction, the chief executive officer now directly owns 18,485,559 shares in the company, valued at approximately $115,349,888.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,158,800 shares of company stock worth $12,946,562. 22.85% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Managed Account Services Inc. bought a new position in TherapeuticsMD in the 3rd quarter valued at about $117,000. Fox Run Management L.L.C. bought a new position in TherapeuticsMD in the 2nd quarter valued at about $121,000. Xact Kapitalforvaltning AB lifted its position in TherapeuticsMD by 96.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after acquiring an additional 15,600 shares in the last quarter. Affiance Financial LLC bought a new position in TherapeuticsMD in the 2nd quarter valued at about $156,000. Finally, Barclays PLC lifted its position in shares of TherapeuticsMD by 33,787.3% during the 1st quarter. Barclays PLC now owns 37,276 shares of the company’s stock worth $182,000 after buying an additional 37,166 shares in the last quarter. 66.13% of the stock is currently owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: Technical Analysis

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply